For many market access teams, success is measured at a familiar milestone:
coverage secured, contracts signed, launch greenlit.
On paper, it looks like a win.
But in practice, some of the most painful access surprises don’t happen before coverage — they happen after.
Drugs with favorable formulary placement underperform. Products with strong early signals stall. Forecasts built on “good access” fail to materialize into real-world uptake.
The issue isn’t that teams don’t know how to win access.
It’s that early access signals don’t always predict what happens next.
Coverage Is Not the Same as Utilization
Formulary status tells you where a product sits.
It doesn’t tell you how it’s used.
Even when coverage looks strong, downstream friction can quietly derail uptake:
- Benefit designs that create unexpected patient cost exposure
- Step edits that appear manageable on paper but create real prescribing barriers
- Site-of-care dynamics that shift utilization away from original assumptions
These aren’t failures of strategy. They’re gaps between policy and behavior.
And most teams don’t see them early enough to respond.
Why Early Signals Can Be Misleading
Access leaders often rely on early indicators to assess performance:
- Initial payer feedback
- Advisory input
- Contract terms
- Early utilization snapshots
The problem? These signals are static, directional, and often incomplete.
They reflect intent — not execution.
What they don’t capture well:
- How providers interpret coverage in real clinical workflows
- Where patients fall out due to cost or complexity
- How utilization patterns differ across health systems, specialties, or geographies
By the time these issues surface clearly, weeks or months have passed — and course correction becomes harder.
The “Last Mile” Is Where Access Strategies Break
The last mile of access isn’t about winning approval.
It’s about sustaining behavior.
This is where many strategies quietly break:
- When prescribers hesitate despite coverage
- When patients abandon therapy despite availability
- When access assumptions don’t align with real-world care pathways
Teams often discover these gaps only after quarterly reporting cycles — long after early intervention would have mattered.
What High-Performing Teams Do Differently
Leading access organizations treat post-launch validation as a core discipline, not a retrospective exercise.
They ask different questions early:
- Is coverage translating into prescribing behavior the way we expected?
- Where are patients encountering friction we didn’t anticipate?
- Which assumptions are holding — and which are already failing?
Instead of waiting for lagging indicators, they focus on understanding how access actually functions in practice.
Because access success isn’t defined by what was negotiated — it’s defined by what happens next.
Rethinking What “Good Access” Really Means
If access strategies are judged only by coverage milestones, teams will always be surprised by real-world performance.
The more durable definition of success is simpler — and harder:
- Coverage that converts
- Value that resonates in clinical reality
- Strategies that adapt when assumptions meet the real world
Good access isn’t the finish line.
It’s the starting point.